US 11,667,616 B2
Oral GSNOR inhibitor and pharmaceutical use thereof
Yong Ji, Jiangsu (CN); Liping Xie, Jiangsu (CN); Shuang Zhao, Jiangsu (CN); Tianyu Song, Jiangsu (CN); and Yi Han, Jiangsu (CN)
Assigned to NANJING MEDICAL UNIVERSITY, Jiangsu (CN)
Appl. No. 17/628,904
Filed by NANJING MEDICAL UNIVERSITY, Jiangsu (CN)
PCT Filed Apr. 25, 2021, PCT No. PCT/CN2021/089594
§ 371(c)(1), (2) Date Jan. 21, 2022,
PCT Pub. No. WO2022/141977, PCT Pub. Date Jul. 7, 2022.
Claims priority of application No. 202011622515.7 (CN), filed on Dec. 31, 2020.
Prior Publication US 2022/0372007 A1, Nov. 24, 2022
Int. Cl. C07D 277/02 (2006.01); A61P 11/06 (2006.01); C07D 417/14 (2006.01)
CPC C07D 277/02 (2013.01) [A61P 11/06 (2018.01); C07D 417/14 (2013.01)] 2 Claims
 
1. A thiazolone derivative of N6022 having a characteristic structure which is:

OG Complex Work Unit Chemistry